ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1656

Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis

Yahui Grace Chiu1, Edward Schwarz2, Dongge Li3, Nelson Huertas3, Cristy Bell4, Debbie Campbell4 and Christopher T. Ritchlin5, 1Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Orthopedeatrics, University of Rochester, Rochester, NY, 3Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 4Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Bone marrow, osteoclasts and psoriasis, RANK/RANKL pathway

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data suggested that the local inflammatory conditions caused by arthritis progression will induce the proliferation of BM-residing OCPs to further mature into multinucleated mature OC with bone erosion activity, which subsequently expedite arthritis progression. No direct evidence is available to support this notion due to the absence of reliable OCP biomarkers and OCP enumeration with high accuracy. It also remains unclear whether the differentiation of OCPs within BM could be affected solely by skin (psoriasis, Ps) but not bone condition (psoriatic arthritis, PsA). We have previously shown that DC-STAMP, a master regulator in osteoclast differentiation, is elevated in patients with psoriatic arthritis (PsA). In addition, we also showed that DC-STAMP has the potential to serve as a diagnostic biomarker to predict the susceptibility of patients with psoriasis to PsA transition. Given that changes in the BM microenvironment might occur at the early stage of Ps to PsA transition, in this study, we investigate whether Ps pathogenesis could affect the microenvironment of bone marrow for OCP differentiation by comparing DC-STAMP expression level and DC-STAMP+ cell frequency in BM and periphery at healthy and disease status.

Methods:

Bone marrow aspirates (BMA) and blood were collected from 13 Ps patients (PASI score between 35-60) and 5 healthy controls (HC). Total cells or enriched CD14+ monocyte were isolated from BMA and blood, analyzed by 12-color flow cytometry ex vivo, and enumerated OC by TRAP staining after 8-day in vitro culture in OC-promoting media.

Results:

There are 5 major results: (1) More OCPs were found in BM than blood, which is common for both HC and Ps patients (column b); (2) Ps patients have a slightly higher OCPs in BM than HC (1800 +/- 1620 vs. 1651 +/- 1101); (3) Mean Fluorescence Intensity (MFI) of DCSTAMP: This measure the expression level of DC-STAMP. Comparable MFI were found between blood and BM in HC, whereas DC-STAMP MFI is reduced, although not significant, in BM in Ps patients (column C); (4) OCP (purified monocytes) in Ps’s BM is higher than HC (1800 +/- 1620 vs. 1651 +/- 1101, column b). However, the total OCP readouts are lower if monocytes were co-cultured with T & B cells (column a); (5) the inflammatory CD14+CD16+ monocyte subset was elevated in the BM of Ps patients.

Conclusion: (1) Ps pathogenesis induces changes in the BM microenvironment which subsequently affects OCgenesis and OCP frequency within the BM; (2) unidentified cellular factors, such as cell subset & chemokine/cytokines, are present in human bone marrow to suppress OC differentiation (Column A, Ps BM) and DC-STAMP expression (Column C, Ps BM); (3) 3 potential Ps-specific biomarkers are (i) % of CD14+CD16+ cells in BM, (ii) difference between DC-STAMP% in BM and blood (Δ(BM-blood) of DC-STAMP%), and (iii) difference between DC-STAMP MFI in BM and blood (Δ(BM-blood) of DC-STAMP MFI).


Disclosure: Y. G. Chiu, None; E. Schwarz, None; D. Li, None; N. Huertas, None; C. Bell, None; D. Campbell, None; C. T. Ritchlin, Amgen, Janssen Pharmaceutica Product, L.P., and UCB, 2,AbbVie, Amgen, Janssen Pharmaceutica Product, L.P., Regeneron, and UCB, 5.

To cite this abstract in AMA style:

Chiu YG, Schwarz E, Li D, Huertas N, Bell C, Campbell D, Ritchlin CT. Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/compare-the-potential-of-osteoclast-precursors-ocps-residing-in-bone-marrow-and-peripheral-blood-as-the-surrogates-of-psoriasis-pathogenesis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/compare-the-potential-of-osteoclast-precursors-ocps-residing-in-bone-marrow-and-peripheral-blood-as-the-surrogates-of-psoriasis-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology